Active Surveillance for Intermediate Risk Prostate Cancer
Current Urology Reports Sep 01, 2017
Klotz L, et al. Â Researchers conducted a clinical study which indicated that patients with intermediateÂrisk prostate cancer (PCa) should not be excluded from active surveillance based on a single criterion. It was demonstrated that treatment decisions should be based on multiple parameters, including percent Gleason 4, PSA density, cancer volume on biopsy, magnetic resonance imaging findings, and patient age and coÂmorbidity. Genetic tissueÂbased biomarkers are also likely to play a role in enhancing decision making.
Go to Original
- In this analysis, outcome findings for intermediate-risk patients managed by active surveillance illustrate reasonable outcomes, but these men clearly are at higher risk for progression to metastatic disease.
- It was considered that the use of biomarkers and multiparametric MRI will enable a more precise and personalized risk assessment.
- Moreover, literature describing the impacts of young age on outcomes is limited, but the experience reported in prospective series with 15Â20 year follow-up suggests it is a safe approach.
- In addition, African-American men are at greater risk for occult co-existent higher-grade disease, but in the absence of this their outcome is favorable.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries